A Rare Form of Insulin Resistance with Pseudoacromegaly **Stephen Stone**¹, Jennifer Wambach², F. Sessions Cole², Daniel Wegner², and Fumihiko Urano³

¹Pediatric Endocrinology and Diabetes, ²Newborn Medicine, ³Endocrinocrinology, Metabolism, and Lipid Research Washington University School of Medicine, St. Louis, MO, USA Stone_S@kids.wustl.edu


Background

Insulin resistance occurs in a variety of common endocrine disorders A including obesity, type 2 diabetes, polycystic ovarian syndrome, and metabolic syndrome. Additionally, rare syndromes exist that result in extreme insulin resistance. These conditions help contribute to our knowledge of the mechanisms of insulin signaling and resistance.

Case


12-year-old girl referred to pediatric endocrine clinic for evaluation of new onset diabetes. She was found to have an elevated random glucose in her pediatrician's office 3 months before. Subsequently she was started on metformin and lisinopril prior to the referral.

- Birth weight: 6lb 7oz (2920 g)
- Obese since kindergarten age Extreme weight gain in the last 2 years



- Nearly continuous growth spurt
- Now having difficulty fitting into her clothes


Premenarchal



The patient's growth chart. Height is noted in blue, well above the Patient photographs: A) Whole body B) Facial features C) Axilla 97th percentile. Weight is shown in red, and is extremely elevat-D) Left Hand E) Left Foot F) Profile

ed. Weight is out of proportion to height.

Family History



Radiology

Bone Age x-ray was consistent with 14 yr. This provides a predicted adult height of 72 inches (1.83 m, +3.23 SDS).

Discussion

• We are reporting on an extremely rare form of severe insulin resistance.

• Most insulin resistance syndromes are associated with short stature.

- This syndrome is unique as it is associated with overgrowth.
- Likely represents downstream defect in insulin signaling:
 - Impaired metabolic effects.
 - Enhanced mitogenic effects.
- Genetic and functional studies may reveal a causative gene(s).
- Potential to teach us about novel aspects of insulin signaling.

Author Disclosures

The authors have no relevant financial disclosures or conflicts of interest.

References

Laboratory Assessments

HbA1c 6.6% (49 mmol/mol)

DHEA-S 99 mcg/dL (2.67 umol/L) Total Testosterone 66 ng/dL (2.29 nmol/L) Free Testosterone 16 pg/mL (55.5 pmol/L) 17-OH Progesterone 69 ng/dL (2.09 (nmol/L) Estradiol 29 pg/mL (106.46 pmol/L) LH 7.7 mIU/mL (IU/L)FSH 5.4 mIU/mL (IU/L)

Glucose 186 mg/dL (10.32 mmol/L) IGF-1 331 ng/mL (43.6 nmol/L)

IGFBP-3 5.3 ug/mL (16038.2 nmol/L)

Leptin 19.0 ng/mL (1.19 mmol/L)

Insulin 1279 uIU/mL (8882.66 pmol/L)

Cholesterol 141 mg/dL (3.64 mmol/L) Triglycerides 189 mg/dL (2.13 mmol/L) HDL 29 mg/dL (0.75 mmol/L) LDL 74 mg/dL (1.91 mmol/L)

AST 31 U/L (0.52 ukat/L) ALT 72 U/L (1.20 ukat/L)

Chromosomal Microarray: No significant duplications or deletions.



2 Hour Oral Glucose Tolerance Test 120 30 60 90 Time (minutes) Glucose (mg/dL) 85 127 120 142 128 27.7* 390 Insulin (mIU/mL) 752* 488 799 0.55 0.24 Growth Hormone (ng/mL) 0.49 < 0.1 0.1 The subject was brought in for a 75g oral glucose tolerance test. Glucose, insulin, and growth hormone were measured at serial time points. This test demonstrated severe insulin resistance, however she appropriately suppressed growth hormone at 90 minutes. *Sample hemolyzed, insulin may be falsely lowered.

1. Flier, J.S., et al., Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab, 1993. 76(6): p. 1533-41.

2. Dib, K., et al., Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance. J Clin Invest, 1998. 101(5): p. 1111-20.



